Outcomes of Living and Deceased Donor Liver Transplant Recipients With Hepatocellular Carcinoma: Results of the A2ALL Cohort

Department of Medicine and Surgery, Northwestern University, Chicago, IL Department of Surgery, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VA Department of Surgery, University of Michigan, Ann Arbor, MI Department of Medicine and Surgery, Columbia University College of Physicians and Surgeons, New York, NY Department of Surgery, University of California, San Francisco, San Francisco, CA Department of Surgery, University of Pennsylvania, Philadelphia, PA Department of Medicine, University of Colorado, Denver, Aurora, CO National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD Department of Surgery, University of California, Los Angeles, CA Department of Medicine, University of North Carolina, Chapel Hill, NC Department of Medicine, University of Virginia, Charlottesville, VA Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
American Journal of Transplantation (Impact Factor: 5.68). 09/2012; 12(11). DOI: 10.1111/j.1600-6143.2012.04272.x
Source: PubMed


Hepatocellular carcinoma (HCC) represents an increasing fraction of liver transplant indications; the role of living donor liver transplant (LDLT) remains unclear. In the Adult-to-Adult Living Donor Liver Transplantation Cohort Study, patients with HCC and an LDLT or deceased donor liver transplant (DDLT) for which at least one potential living donor had been evaluated were compared for recurrence and posttransplant mortality rates. Mortality from date of evaluation of each recipient's first potential living donor was also analyzed. Unadjusted 5-year HCC recurrence was significantly higher after LDLT (38%) than DDLT (11%), (p = 0.0004). After adjustment for tumor characteristics, HCC recurrence remained significantly different between LDLT and DDLT recipients (hazard ratio (HR) = 2.35; p = 0.04) for the overall cohort but not for recipients transplanted following the introduction of MELD prioritization. Five-year posttransplant survival was similar in LDLT and DDLT recipients from time of transplant (HR = 1.32; p = 0.27) and from date of LDLT evaluation (HR = 0.73; p = 0.36). We conclude that the higher recurrence observed after LDLT is likely due to differences in tumor characteristics, pretransplant HCC management and waiting time.

Download full-text


Available from: Gregory T Everson, Oct 12, 2014
1 Follower
15 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To accompany the article by Kulik et al on page 2997, the author provides a summary of the experience of living donor liver transplantation for patients with hepatocellular carcinoma.
    American Journal of Transplantation 11/2012; 12(11):2873-4. DOI:10.1111/j.1600-6143.2012.04277.x · 5.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and is considered an aggressive tumor with mean survival estimated between 6 and 20 months. Hepatitis B and C are the most common etiologies. Pathological, laboratory and radiologic imaging all aid in diagnosis but much controversy exists in the utilization of any given modality. Many treatment options exist for management of HCC, each has its own limitation. Liver transplantation offers the most reasonable expectation for curative treatment while simultaneously removing the burden of the diseased liver. Still, advancements in the field have thus far not yet matched its potential, although new immunosuppressive and chemotherapy regimen may allow transplantation to push the envelope once again.
    02/2013; 2(1):22-30. DOI:10.3978/j.issn.2304-3881.2012.11.03
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in the world. Early detection and timely treatment of HCC is critical for better patient outcomes. Curative therapy consists of surgical hepatic resection or liver transplantation (LTx); however, both are restricted to explicit selective criteria. Liver resection is the gold standard of treatment for noncirrhotic patients but can be done in only a small fraction of cirrhotic patients depending on synthetic dysfunction, degree of portal hypertension, and number and location(s) of tumor(s). Therefore, the best treatment modality in cirrhotic patients with HCC is LTx as it will cure both HCC and the underlying cirrhosis. The limitation to offer transplant to all cirrhotic patients with HCC is the shortage of available donor organs. While these patients are waiting for transplant, their tumors may progress and develop distant metastases and may lead to patients losing their candidacy for LTx. Various ablation therapies can be used to treat HCC, prevent tumor progression, and thus, avoid patients losing the option of LTx. Future directions to improve HCC patient outcomes include advancement in tumor gene analysis and histopathology for better prediction of tumor behavior, improved immunosuppression regimens to reduce tumor recurrence in the posttransplant setting, and efficient use of an expanded donor pool that includes living donor organs. This paper will review the current methods of HCC diagnosis, selection for either hepatic resection or LTx, and will also summarize posttreatment outcomes. We will suggest future directions for the field as we strive to improve outcomes for our HCC patients.
    Journal of clinical gastroenterology 04/2013; 47. DOI:10.1097/MCG.0b013e318286ff8e · 3.50 Impact Factor
Show more